AlphAIAlphAI — Financial news for AI agents
hcplive.comOCT 92 min read$JNJ

ICONIC-LEAD: Icotrokinra Sustains Psoriasis Skin Clearance at 2 Years

Johnson & Johnson's icotrokinra (Icotyde) showed sustained skin clearance and itch improvement in moderate-to-severe plaque psoriasis patients over 2 years, according to phase 3 ICONIC-LEAD study data. At least 72% of patients achieved PASI 90 and 70% achieved IGA 0/1. The drug is approved in the US, Europe, Japan, and China for adults and adolescents.

Original reporting
hcplive.com
Published Oct 9, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 12:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ICONIC-LEAD: Icotrokinra Sustains Psoriasis Skin Clearance at 2 Years — source image
Source · hcplive.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The 2‑year durability data reinforce the drug's positioning as a first‑line systemic option, potentially expanding market share.

02

Market read

New clinical data could drive short‑term price movement in JNJ and influence investor sentiment toward dermatology biotech.

03

What to watch

Reimbursement negotiations and competition from newer IL‑23 inhibitors could limit upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Johnson & Johnson's icotrokinra (ICOTYDE) is an oral IL‑23 receptor antagonist approved for moderate‑to‑severe plaque psoriasis.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson announced new 2‑year phase‑3 ICONIC‑LEAD data showing high skin‑clearance rates for its psoriasis drug icotrokinra.

Expected impact

likely upside as market prices in durable efficacy data

Evidence & confidence

Phase‑3 data are first‑time disclosure; investors typically reward biotech breakthroughs with share price gains.

Market effects

Sector

strengthens outlook for psoriasis and broader dermatology therapeutics, may lift peer biotech stocks

Regional

U.S. market, with potential spillover to European and Asian markets where the drug is approved

Global

global relevance due to multi‑region approvals and potential expansion into psoriatic arthritis

Counterpoint

What could challenge this read

If the data do not translate into commercial uptake, the hype could fade and the stock may underperform.

Key entities

  • Company
    Johnson & Johnson

    Manufacturer of icotrokinra, US‑listed (JNJ).

  • Institution
    Icahn School of Medicine

    Provided expert commentary on trial durability.

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Also covered by

3 outlets

Related articles

OCT 11
$JNJMedAI 9/10

Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years

Johnson & Johnson (JNJ) reported that its oral psoriasis drug, ICOTYDE, maintained skin clearance through 112 weeks in a Phase 3 study, with 89% of genital psoriasis patients and 60% of scalp psoriasis patients achieving complete clearance. The study, presented at a dermatology congress, showed improved outcomes in difficult-to-manage areas, with no new safety concerns identified. JNJ aims to differentiate ICOTYDE in the psoriasis treatment market with its oral delivery.

mychesco.com2 min
OCT 9
$JNJMed

Johnson & Johnson's Icotyde Shows Strong Phase 3 Results for Pla

Johnson & Johnson (JNJ) reported positive phase 3 trial results for Icotyde (icotrokinra) in treating plaque psoriasis, with 72% of patients achieving PASI 90. JNJ offers a 1.95% dividend yield with a 55% payout ratio and a GF Score™ of 83. Despite a 34.1% premium to its GF Value™, the dividend is deemed sustainable. Insider and guru activity shows net selling.

gurufocus.com3 min
OCT 9
$JNJMed

Johnson & Johnson Announces New Two-Year Results from Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE in Adults and Adolescents with Moderate-To-Severe Plaque Psoriasis

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE® in moderate-to-severe plaque psoriasis. Data showed high skin clearance rates and sustained symptom improvement with no new safety signals. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The study included 684 participants, with 66 adolescents. ICOTYDE is approved in the U.S., Europe, Japan, and China for psoriasis treatment.

marketscreener.com2 min
OCT 9
$BSXMed

Boston sues J&J subsidiary over alleged patent infringement for cardiology device

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

finance.yahoo.com2 min
OCT 9
$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

mugglehead.com2 min